People with acid reflux often rely on acid-reducing medications to ease symptoms. Depending on the severity of your symptoms, ...

As gastroenterology research progresses, it is critical to comprehend the connection between stomach cancer and gastric ...

Objective To determine whether new users of proton pump inhibitors (PPIs ... PPIs are one of the most commonly prescribed drug classes worldwide, and uncertainties relating to their association with ...

Based on the perceived low efficacy of current therapies targeted to FGFR2 in gastric cancer (GC), the authors investigate an approach which combines SHP2 inhibition with existing FGFR2 inhibitors.

1Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China. 2Department of Cell Biology, Zhejiang University School of Medicine, ...

for the treatment of diffuse gastric cancer (DGC) and other advanced solid tumors. This marks a significant milestone as SIGX1094 is the first pipeline drug discovered using AI and organoid disease ...

Currently, there are no approved TKIs that inhibit the full spectrum of clinically relevant primary and secondary mutations in KIT. IDRX-42 has demonstrated activity against all key primary and ...

For most patients, PPIs and histamine-2 receptor antagonists remain the primary way to inhibit gastric acid secretion for common ... anti-inflammatory drug–associated ulcers — P-CABs can ...